secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015507
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax Q2 net loss $37.6M ($0.62/sh); on track for pivotal data in 1H23
-----------------------------------------------------------------------

- Cash $378.9M; net loss $37.6M ($0.62/sh) vs $22.9M ($0.44/sh) year ago.
- R&D expenses $29.7M (up from $16.9M); G&A $8.0M (up from $5.8M).
- On track to report topline data from revumenib and axatilimab pivotal programs in 1H23.
- Updated revumenib Phase 1 data expected 4Q22; axatilimab IPF trial start in 4Q22.
- Appointed Keith A. Goldan as CFO in June 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017022015507/0000950170-22-015507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017022015507/sndx-20220808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer